tiprankstipranks
10x Genomics Inc (GB:0A88)
LSE:0A88

10x Genomics (0A88) Share Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

0A88 Analyst Ratings

Moderate Buy
11Ratings
8 Buy
2 Hold
1 Sell
Based on 11 analysts giving stock ratings to
10x
Genomics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0A88 Stock 12 Month Forecast

Average Price Target

$54.09
▲(81.71% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for 10x Genomics in the last 3 months. The average price target is $54.09 with a high forecast of $70.00 and a low forecast of $30.00. The average price target represents a 81.71% change from the last price of $29.77.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"29":"$29","50":"$50","71":"$71","39.5":"$39.5","60.5":"$60.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$70.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":54.09,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$54.09</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$30.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[29,39.5,50,60.5,71],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.25,38.84615384615385,41.44230769230769,44.03846153846154,46.63461538461539,49.23076923076923,51.82692307692308,54.42307692307692,57.019230769230774,59.61538461538461,62.21153846153847,64.8076923076923,67.40384615384616,{"y":70,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.25,37.62230769230769,38.994615384615386,40.36692307692308,41.73923076923077,43.111538461538466,44.48384615384616,45.856153846153845,47.228461538461545,48.60076923076923,49.97307692307693,51.34538461538462,52.71769230769231,{"y":54.09,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,36.25,35.76923076923077,35.28846153846154,34.80769230769231,34.32692307692308,33.84615384615385,33.36538461538461,32.88461538461539,32.40384615384615,31.923076923076923,31.442307692307693,30.96153846153846,30.48076923076923,{"y":30,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":53.605,"date":1681430400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.495,"date":1683244800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.485,"date":1685664000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.59,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.49,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":54.03,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.77,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.802,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.26,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.325,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.7,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.34,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.25,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$70.00Average Price Target$54.09Lowest Price Target$30.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wolfe Research
$55.00
Buy
84.76%
Upside
Initiated
12/12/23
10x Genomics initiated with bullish view at Wolfe Research10x Genomics initiated with bullish view at Wolfe Research
J.P. Morgan
$65.00
Buy
118.36%
Upside
Reiterated
11/03/23
10X Genomics (TXG) PT Lowered to $65 at JPMorganJPMorgan analyst Rachel Vatnsdal lowered the price target on 10X Genomics (NASDAQ: TXG) to $65.00 (from $70.00) while maintaining a Overweight rating.
Stephens
$65.00
Buy
118.36%
Upside
Reiterated
05/18/23
Wall Street Analysts Are Bullish on Top Healthcare Picks
Guggenheim Analyst forecast on GB:0A88
Unknown Analyst
Not Ranked
Guggenheim
$60.00
Buy
101.56%
Upside
Initiated
12/13/23
10x Genomics initiated with bullish view at Guggenheim10x Genomics initiated with bullish view at Guggenheim
CFRA
Buy
Upgraded
03/26/24
CFRA upgrades 10X Genomics (TXG) to BuyCFRA upgraded 10X Genomics (NASDAQ: TXG) from Hold to Buy with a price target of $43.00.

Best Analysts Covering 10x Genomics

Which Analyst Should I Follow If I Want to Buy GB:0A88 and Sell After:
1 Month
Success Rate
8/15 ratings generated profit
53%
Average Return
+1.06%
reiterated a buy rating 2 months ago
Copying Patrick B Donnelly's trades and holding each position for 1 Month would result in 53.33% of your transactions generating a profit, with an average return of +1.06% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Success Rate
8/15 ratings generated profit
53%
Average Return
+0.23%
reiterated a buy rating 2 months ago
Copying Patrick B Donnelly's trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of +0.23% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Doug SchenkelWolfe Research
Success Rate
5/8 ratings generated profit
63%
Average Return
+55.55%
initiated a buy rating 4 months ago
Copying Doug Schenkel's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of +55.55% per trade.
2 Years
Doug SchenkelWolfe Research
Success Rate
3/8 ratings generated profit
38%
Average Return
+31.06%
initiated a buy rating 4 months ago
Copying Doug Schenkel's trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of +31.06% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0A88 Analyst Recommendation Trends

Rating
Dec 23
Jan 24
Feb 24
Mar 24
Apr 24
Strong Buy
4
5
1
1
0
Buy
5
6
12
10
9
Hold
2
3
4
3
2
Sell
1
1
1
1
1
Strong Sell
0
0
0
0
0
total
12
15
18
15
12
In the current month, 0A88 has received 9 Buy Ratings, 2 Hold Ratings, and 1 Sell Ratings. 0A88 average Analyst price target in the past 3 months is $54.09.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

0A88 Financial Forecast

0A88 Earnings Forecast

Next quarter’s earnings estimate for 0A88 is -$0.50 with a range of -$0.65 to -$0.30. The previous quarter’s EPS was -$0.41. 0A88 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 36.00% of the time in the same period. In the last calendar year 0A88 has Underperformed its overall industry.
Next quarter’s earnings estimate for 0A88 is -$0.50 with a range of -$0.65 to -$0.30. The previous quarter’s EPS was -$0.41. 0A88 beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 36.00% of the time in the same period. In the last calendar year 0A88 has Underperformed its overall industry.

0A88 Sales Forecast

Next quarter’s sales forecast for 0A88 is $142.24M with a range of $136.97M to $145.95M. The previous quarter’s sales results were $183.98M. 0A88 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.84% of the time in the same period. In the last calendar year 0A88 has Outperformed its overall industry.
Next quarter’s sales forecast for 0A88 is $142.24M with a range of $136.97M to $145.95M. The previous quarter’s sales results were $183.98M. 0A88 beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 46.84% of the time in the same period. In the last calendar year 0A88 has Outperformed its overall industry.

0A88 Stock Forecast FAQ

What is GB:0A88’s average 12-month price target, according to analysts?
Based on analyst ratings, 10x Genomics Inc’s 12-month average price target is $54.09.
    What is GB:0A88’s upside potential, based on the analysts’ average price target?
    10x Genomics Inc has 81.71% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is 10x Genomics Inc a Buy, Sell or Hold?
          10x Genomics Inc has a conensus rating of Moderate Buy, which is based on 8 buy ratings, 2 hold ratings and 1 sell ratings.
            What is 10x Genomics Inc’s share price target?
            The average share price target for 10x Genomics Inc is $54.09. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $70.00 ,and the lowest forecast is $30.00. The average share price target represents 81.71% Increase from the current price of $29.768.
              What do analysts say about 10x Genomics Inc?
              10x Genomics Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of 10x Genomics Inc?
                To buy shares of GB:0A88, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis